- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05573425
Comparing the Efficacy of Topical Tazarotene Gel 0.1% v/s Microneedling in Atrophic Post Acne Scars
Comparing the Efficacy of Topical Tazarotene Gel 0.1% Versus Microneedling in Atrophic Post Acne Scars
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This was a randomized Control Trial, done in Department of Dermatology, Jinnah Postgraduate Medical Centre (JPMC), Karachi from August 22, 2020 to February 21, 2021.
A total of 202 patients with 101 in each group. The sample size was estimated using WHO sample size calculator using statistics for efficacy in topical Tazarotene gel (group A) as 30.5% and micro-needling (group B) as 47.2%,80% power of test and 95% confidence level. Both genders, 18 to 40 years with atrophic post-acne scar patients of duration 4 to 8 years were included. Informed consent was obtained. Patients with grade 2 to 4 facial atrophic post-acne scars assessed by Goodman and Baron qualitative global scarring grading system. While excluded pregnant/lactating woman, any prior allergy to given drug, history of keloidal tendency/hypertrophic scarring, active acne or acne marks such as red, black or brown macular marks, previous dermabrasion, laser resurfacing on face, facial scar due to reasons other than acne, collagen vascular disease, bleeding disorders, treatment history of <4 weeks for topical retinoid, alpha/beta hydroxyl acids, <3 months for microdermabrasion and <6 months for oral retinoids.
This study was conducted after approval from ethical review committee and CPSP. During the patient first visit, baseline photographs were captured with informed consent. Dermoscopic examinations of predominant scar type (such as icepick, rolling or boxcar) and the ssca severity assessed according to the Goodman and Baron qualitative acne scarring grading systems for every patient. All patients were randomly divided into two groups using computer-generated sequential number placed in sealed envelopes and opened only before the commencement of the study. In group A, patients were instructed to apply a thin film of tazarotene gel 0.1% over the affected area once daily in the evening by placing a pea-sized amount of gel in the palm of the hand and using tip of a finger to cover the entire half of the face. Patients who experienced facial dryness were allowed to use a moisturizing cream during the day on entire face but use of any other medication on the face was prohibited. In group B, microneedling was performed with a standard dermaroller (192 needles of length 1.5 mm) by the same investigator, once per month for 6 months. A topical anesthetic mixture of lignocaine and prilocaine was applied over the face in a thick layer under occlusion 1 hour before the procedure.
Microneedling was performed by rolling the dermaroller with uniform and firm pressure in 4 different directions (i.e, perpendicular and diagonal to each other) with to-and-fro motion up to 8 times (a total of 32 passes) or until the end point of uniform pinpoint bleeding was achieved. After treatment, the area was wetted with saline pads. The participants were instructed to follow strict photoprotective measures including the application of a broad-spectrum sunscreen with sun protection factor 30 over the entire face. All patients were followed up at 3 month and on 6 month from the baseline visit. Digital photographs were captured at 3 and 6 month follow-up visits. An improvement by 2 qualitative grades was considered excellent, by 1 grade was rated good, and by 0 grade was labeled a poor response. The outcome was the change from baseline in acne scar severity grade at 3 and 6 month follow-up visits. All the data was entered in a predesigned proforma. Biasness and confounder were controlled by strictly following the inclusion criteria.
SPSS version 21 was used for data compilation and analysis. Frequencies and percentages were computed for qualitative variables like gender, scar type, treatment, scar severity grade at baseline, after 3 and 6 months and efficacy. Quantitative variables were presented as mean ± SD like age and duration of acne. Comparison between both groups for efficacy was done by using Chi square test. Effect modifier like age, gender and duration of disease were controlled through stratification. Post stratification, Chi square test was applied for categorical variables. Consider P <0.05 as significant.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
Sindh
-
Karachi, Sindh, Pakistan, 75510
- Jinnah Post Graduate Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Both genders.
- Age from 18 to 40 years.
- Atrophic post-acne scar patients with duration 4 to 8 years.
- Informed consent will be obtained.
- Patients with grade 2 to 4 facial atrophic post-acne scars as assessed by the Goodman and Baron qualitative global scarring grading system.
Exclusion Criteria:
- Pregnant or lactating woman.
- Patients having any allergy related to given drug.
- History of keloidal tendency or hypertrophic scarring.
- Those with active acne or acne marks such as red, black or brown macular marks.
- Patients with a previous history of dermabrasion or laser resurfacing on the face.
- Facial scar due to reasons other than acne, collagen vascular disease or bleeding disorder.
- Patients with a treatment history of <4 weeks for topical retinoid and alpha/beta hydroxy acids, <3 months for microdermabrasion and <6 months for oral retinoids.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Group on Treatment:Tazarotene Gel
In group A, patients were instructed to apply a thin film of tazarotene gel 0.1% over the affected area once daily in the evening by placing a pea-sized amount of gel in the palm of the hand and using tip of a finger to cover the entire half of the face. Patients who experienced facial dryness were allowed to use a moisturizing cream during the day on entire face but use of any other medication on the face was prohibited. Intervention - Tazarotene gel 0.1% |
Tazarotene gel 0.1% applied daily on Acne Scars.
Other Names:
|
Active Comparator: Group on Treatment:Microneedling
In group B, microneedling was performed with a standard dermaroller (192 needles of length 1.5 mm) by the same investigator, once per month for 6 months. A topical anesthetic mixture of lignocaine and prilocaine was applied over the face in a thick layer under occlusion 1 hour before the procedure. Microneedling was performed by rolling the dermaroller with uniform and firm pressure in 4 different directions (i.e, perpendicular and diagonal to each other) with to-and-fro motion up to 8 times (a total of 32 passes) or until the end point of uniform pinpoint bleeding was achieved. After treatment, the area was wetted with saline pads. The participants were instructed to follow strict photoprotective measures including the application of a broad-spectrum sunscreen with sun protection factor 30 over the entire face. Intervention - Microneedling via dermarolller |
Microneedling via dermaroller device performed on Acne Scars monthly.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in morphology of Acne Scars
Time Frame: 12 weeks
|
There is a change in Acne Scars assessed by Goodman and Baron Qualitative Acne Scars Grading system
|
12 weeks
|
Collaborators and Investigators
Investigators
- Study Director: Rabia Ghafoor, Jinnah Postgraduate Medical Centre
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Jpmc
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acne Scar
-
Seoul National University HospitalCompleted
-
Haute Beauté Skin & Vein ClinicTaipei Medical University Shuang Ho Hospital; Lumenis Be Ltd.Unknown
-
Goldman, Butterwick, Fitzpatrick and GroffNot yet recruitingAtrophic Acne Scar
-
Shin Kong Wu Ho-Su Memorial HospitalSpirit ScientificCompleted
-
Mahidol UniversityCompleted
-
Seoul National University HospitalCompletedScar | AcneKorea, Republic of
-
Bellus Medical, LLCCompleted
-
South China Research Center for Stem Cell and Regenerative...UnknownSenescence Wrinkles, Acne, Pitting Scar
-
Thaís Hofmann CachafeiroUnknown
-
University of California, IrvineUniversity of Minnesota; Reliant Technologies, Inc. Mountain View, CACompleted
Clinical Trials on Tazarotene gel 0.1%
-
Postgraduate Institute of Medical Education and...CompletedAtrophic Post Acne ScarringIndia
-
KGL, Inc.NYU Langone Health; Milton S. Hershey Medical Center; Allergan; State University... and other collaboratorsCompletedAcne VulgarisUnited States
-
Galderma R&DCompleted
-
AllerganCompletedAcne VulgarisUnited States
-
University of UtahTerminated
-
G & W Laboratories Inc.Completed
-
Assiut UniversityUnknown
-
Dr. Reddy's Laboratories LimitedCompletedAcne VulgarisUnited States
-
Dr. Reddy's Laboratories LimitedCompletedAcne VulgarisUnited States